News

Despite FDA ruling, compounded GLP-1s are still giving Novo and Lilly headaches on the market

When the FDA took Novo Nordisk and Eli Lilly’s GLP-1 medications off of the drug shortage list, the move should have been a ...

Wall Street sees new obesity pills as priced near Wegovy and Zepbound

U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...

Novo Nordisk Stock Is Jumping. Weight-Loss Drug Wegovy Has Something to Do With It.

Novo Nordisk makes the wildly popular GLP-1 drug semaglutide which it sells under the brand name Wegovy for weight-loss and ...

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease ...

Investors Who Lost Money on Hims & Hers Health, Inc. (HIMS) Should Contact Levi & Korsinsky About Pending Class Action - HIMS

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Hims & Hers Stock Slips As FTC Probe Into Subscription Practices Resurfaces

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...
Devdiscourse5d

Healthcare Highlights: Assura Bid, Wegovy Lawsuits, and AI in Hospitals

This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...
The Daily Reflector6d

HIMS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc.

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the ...